Delivering immunosuppressant treatment via targeted nanoparticles could open the door to a long-lasting cure for type 1 diabetes. Transplanting insulin-producing cells is a promising approach to treat the disease; however, it is plagued by issues of immune rejection. In a new study, published January 17 in Nature Nanotechnology, mice treated with a reengineered therapy could tolerate a transplant for much longer with fewer side effects … For the 1.6 million people in the U.S. living with type 1 diabetes, keeping the body’s blood sugar levels within the right window at all times can be an ongoing challenge … read more